Showing 10 posts of 10 posts found.

Study shows significant improvement of survival in infants with SMA

July 29, 2021

Results from the Evrysdi part 2 global FIREFISH study show significant improvement in survival and motor milestones in babies with …

NICE finds more SMA patients eligible for £75,000 a vial drug

May 4, 2021
Manufacturing and Production, Sales and Marketing NICE, sma

NICE has announced that more people with the rare genetic disorder spinal muscular atrophy (SMA) are to benefit from nusinersen, …

Roche building

Roche’s SMA treatment Evrysdi approved by European Commission

March 30, 2021
Manufacturing and Production EMA, European Commission, PTC Therapeutics, Roche, sma, spinal muscular atrophy

The European Commission has granted marketing authorisation to Roche and PTC Therapeutics’ Evrysdi, for the treatment of patients aged 2 …

Roche and PTC’s SMA treatment shows positive trial results

March 16, 2021
Manufacturing and Production PTC, PTC Therapeutics, Roche, sma, spinal muscular atrophy

Roche and PTC Therapeutics’s Evrysdi treatment for children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) …

Novartis plans giveaways of world’s most expensive drug

December 19, 2019
Business Services Novartis, Zolgensma, sma

Novartis plans to giveaway 50 doses of the world’s costliest single-dose treatment, Zolgensma, for babies under 2 years old, with …

Novartis exec pushed out over Zolgensma data scandal denies wrongdoing

August 21, 2019
Research and Development AveXis, FDA, Novartis, Zolgensma, data scandal, pharma, sma

Dr Brian Kaspar, the Novartis exec pushed out of AveXis over the Zolgensma data scandal, has said in a statement …


Novartis’ $2.15m SMA drug Zolgensma becomes most expensive FDA-approved therapy

May 28, 2019
Manufacturing and Production AveXis, FDA, Zolgensma, access, drugs, pricing, sma

The FDA has approved Novartis subsidiary AveXis’ $2.15 million gene therapy Zolgensma for children with spinal muscular atrophy (SMA). The …

NHS England agree to pay for Biogen’s $750,000 a year SMA treatment Spinraza

May 15, 2019
Research and Development Biogen, NHS England, Spinraza, UK, pharma, sma, spinal muscular atrophy

NHS England has agreed to pay an undisclosed price for Biogen’s spinal muscle atrophy (SMA) treatment Spinraza. England’s National Health …

Protesters in Manchester call on NICE to approve Biogen’s $750,000 drug Spinraza

September 11, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing NICE, Spinraza, approval, protest, sma

Protesters in Manchester have called on the National Institute of Health and Care Excellence (NICE), to overturn their rejection of …

Roche image

Roche buys French biotech for €470 million

January 19, 2015
Sales and Marketing Foundation, Genentech, Orphan, Roche, TRO19622, olesoxime, sma, trophos

Roche is buying France-based biotech Trophos in a deal worth up to €470 million in order to gain access to …

Latest content